LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting therapies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
Materials in this section
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
Every minute a child in Sub-Saharan Africa dies from malaria; these are preventable deaths! More
MPP and MedinCell Sign Licence Agreement for mdc-STM, an Investigational Long-Acting Injectable Formulation to Fight Malaria Transmission
The non-exclusive licence agreement will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM. More
LAT CAB Video Presentation
In a video, LAT CAB members describe the goal of the CAB, and how long-acting therapies for malaria, latent TB prevention and HCV cure will benefit affected communities. More
Scientists Create Long-Acting Injectable Drug Delivery System for TB
Researchers showed in vivo efficacy of a long-acting injectable formulation of the TB drug rifabutin. More
Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
TAG released a trials tracker providing information on the development of long-acting HCV, malaria, and opioid use and overdose prevention therapy formulations. More
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
World Malaria Day 2022 LAT CAB Statement
In reflection of World Malaria Day, LAT CAB issues a statement calling for a multi-pronged malaria eradication approach. More
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
A survey sought to understand the acceptability of approaches to long-acting HCV treatment. More
Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries
TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More
Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More
